Clinuvel Pharmaceuticals Ltd
ASX:CUV

Watchlist Manager
Clinuvel Pharmaceuticals Ltd Logo
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Watchlist
Price: 12.355 AUD 1.02% Market Closed
Market Cap: 620.2m AUD
Section:
 

Relative Value

The Relative Value of one CUV stock under the Base Case scenario is 16.351 AUD. Compared to the current market price of 12.355 AUD, Clinuvel Pharmaceuticals Ltd is Undervalued by 24%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CUV Relative Value
Base Case
16.351 AUD
Undervaluation 24%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

6.5
P/S
P/S
Price to Sales
6.5
vs History
80
vs Industry
55
Median 3Y
8
Median 5Y
11
Industry
8
Forward
5.9
More Details
17.1
P/E
P/E
Price to Earnings
17.1
vs History
80
vs Industry
9
Median 3Y
22
Median 5Y
29.6
Industry
23.5
Forward
15.7
More Details
15.1
P/OCF
P/OCF
Price to OCF
15.1
vs History
90
vs Industry
8
Median 3Y
20.2
Median 5Y
23.8
Industry
21.9
More Details
15.2
P/FCFE
P/FCFE
Price to FCFE
15.2
vs History
90
vs Industry
8
Median 3Y
22.4
Median 5Y
24.6
Industry
24.3
More Details
2.6
P/B
P/B
Price to Book Value
2.6
vs History
88
vs Industry
33
Median 3Y
3.9
Median 5Y
5.5
Industry
3.2
More Details
4.2
EV/S
EV/S
Enterprise Value to Sales
4.2
vs History
84
vs Industry
55
Median 3Y
6.1
Median 5Y
9.1
Industry
8.1
Forward
3.8
More Details
4.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.2
vs History
84
vs Industry
59
Median 3Y
5.8
Median 5Y
8.3
Industry
10.1
More Details
8.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
8.6
vs History
79
vs Industry
13
Median 3Y
10.5
Median 5Y
15.6
Industry
5.9
Forward
8.3
More Details
8.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
8.6
vs History
79
vs Industry
11
Median 3Y
10.5
Median 5Y
15.6
Industry
6.2
Forward
8.9
More Details
9.6
EV/OCF
EV/OCF
Enterprise Value to OCF
9.6
vs History
90
vs Industry
11
Median 3Y
15.5
Median 5Y
18.7
Industry
7.7
More Details
9.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
9.7
vs History
90
vs Industry
8
Median 3Y
16.5
Median 5Y
19.1
Industry
6.3
More Details
10.5
EV/IC
EV/IC
Enterprise Value to IC
10.5
vs History
90
vs Industry
17
Median 3Y
14.9
Median 5Y
25.6
Industry
5.6
More Details

Multiples Across Competitors

CUV Competitors Multiples
Clinuvel Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Clinuvel Pharmaceuticals Ltd
ASX:CUV
619.3m AUD 6.5 17.1 8.6 8.6
IL
Can Fite Biopharma Ltd
TASE:CANF
707T ILS 255 217 482.5 -17 526 694.5 -17 199 054.4 -17 160 769.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 944 814.2 -161 334.7 -195 911.8 -193 676.2
US
Abbvie Inc
NYSE:ABBV
395.8B USD 6.6 168.6 16.3 23.2
US
Amgen Inc
NASDAQ:AMGN
177.6B USD 4.9 25.4 18.3 18.3
US
Gilead Sciences Inc
NASDAQ:GILD
150.7B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD 10.1 32.4 23.8 24.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 075.4 -529.6 -576.7 -561.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.8B USD 5.7 17.9 17.1 19.3
AU
CSL Ltd
ASX:CSL
82.3B AUD 3.6 18.5 12.5 15.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53.6B USD 16.7 1 229.4 165.8 201.1
P/S Multiple
Revenue Growth P/S to Growth
AU
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Average P/S: 26 287 675.6
6.5
15%
0.4
IL
C
Can Fite Biopharma Ltd
TASE:CANF
255 217 482.5
140%
1 822 982
FR
Pharnext SCA
OTC:PNEXF
33 944 814.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.1
10%
1
US
E
Epizyme Inc
F:EPE
2 075.4
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.7
46%
0.4
P/E Multiple
Earnings Growth PEG
AU
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Average P/E: 191
17.1
17%
1
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 526 694.5 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 334.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.6
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.4
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32.4
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -529.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
10%
1.8
AU
CSL Ltd
ASX:CSL
18.5
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 229.4
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Average EV/EBITDA: 34.4
8.6
17%
0.5
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 199 054.4 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 911.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.3
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.8
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -576.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
11%
1.6
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
165.8
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Average EV/EBIT: 40.4
8.6
13%
0.7
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 160 769.7 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 676.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.3
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.8
16%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.3
13%
1.5
AU
CSL Ltd
ASX:CSL
15.6
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
201.1
N/A N/A

See Also

Summary
CUV intrinsic value, competitors valuation, and company profile.
DCF Valuation
CUV stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CUV stock valuation using valuation multiples.
Wall Street Estimates
CUV price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CUV stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 307,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.